These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 7667210)
1. [Immunohistochemical detection of pS2 protein in paraffin sections of breast carcinoma tissue. Comparison with results of an immunoradiometry assay]. Ahr A; Scharl A; Göhring UJ; Crombach G; Stoffl M Pathologe; 1995 Jul; 16(4):278-84. PubMed ID: 7667210 [TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical and biochemical analysis of the oestrogen regulated protein pS2, and its relation with oestrogen receptor and progesterone receptor in breast cancer. Detre S; King N; Salter J; MacLennan K; McKinna JA; Dowsett M J Clin Pathol; 1994 Mar; 47(3):240-4. PubMed ID: 8163696 [TBL] [Abstract][Full Text] [Related]
3. [Study of the cytosolic concentrations of the tissue poly-peptide specific (TPS) antigen in infiltrating ductal carcinomas of the breast. Positive relationship with hormone dependency and negative with cellular proliferation]. Ruibal A; Arias JI; Resino C; Lapeña G; Schneider J; Tejerina A Rev Esp Med Nucl; 2001 Aug; 20(5):365-8. PubMed ID: 11470070 [TBL] [Abstract][Full Text] [Related]
4. [Analysis of the cytosolic content of the pS2 protein in breast cancer]. Tamargo F; Vizoso F; Lamelas ML; Rodil A; Vérez P; Raigoso P; Mulero M; Vázquez J; Roiz C; Allende MT Rev Esp Med Nucl; 2002 Feb; 21(1):28-33. PubMed ID: 11820999 [TBL] [Abstract][Full Text] [Related]
5. [Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma]. Göhring UJ; Scharl A; Ahr A Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):177-83. PubMed ID: 8682282 [TBL] [Abstract][Full Text] [Related]
6. pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients. Soubeyran I; Quénel N; Coindre JM; Bonichon F; Durand M; Wafflart J; Mauriac L Br J Cancer; 1996 Oct; 74(7):1120-5. PubMed ID: 8855985 [TBL] [Abstract][Full Text] [Related]
7. [Cytosolic pS2 levels and cellular proliferation in ER-positive and PgR-positive infiltrating ductal carcinomas of the breast]. Sánchez Salmón A; Argibay S; Arias JI; Ruibal A Rev Esp Med Nucl; 2005; 24(3):185-90. PubMed ID: 15847785 [TBL] [Abstract][Full Text] [Related]
8. [PS2 as a prognostic factor in 1065 cases of human breast cancer. A multicenter study]. Besse G; Kwiatkowski F; Gaillard G; Daver A; Dalifard I; Basuyau JP; Brunelle P; Wafflart J; Angibeau RM; Auvray E Bull Cancer; 1994 Apr; 81(4):289-96. PubMed ID: 7703545 [TBL] [Abstract][Full Text] [Related]
9. Immunoradiometric detection of pS2 and total cathepsin D in primary breast cancer biopsies: their correlation with steroid receptors. Marsigliante S; Biscozzo L; Correale M; Paradiso A; Leo G; Abbate I; Dragone CD; Storelli C Br J Cancer; 1994 Mar; 69(3):550-4. PubMed ID: 8123486 [TBL] [Abstract][Full Text] [Related]
10. PS2 in breast cancer--alternative or complementary tool to steroid receptor status? Evaluation of 446 cases. Gion M; Mione R; Pappagallo GL; Gatti C; Nascimben O; Bari M; Leon AE; Vinante O; Bruscagnin G Br J Cancer; 1993 Aug; 68(2):374-9. PubMed ID: 8347494 [TBL] [Abstract][Full Text] [Related]
11. Prediction of relapse and survival in breast cancer patients by pS2 protein status. Foekens JA; Rio MC; Seguin P; van Putten WL; Fauque J; Nap M; Klijn JG; Chambon P Cancer Res; 1990 Jul; 50(13):3832-7. PubMed ID: 2354435 [TBL] [Abstract][Full Text] [Related]
12. Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas. Hurlimann J; Gebhard S; Gomez F Histopathology; 1993 Sep; 23(3):239-48. PubMed ID: 8225242 [TBL] [Abstract][Full Text] [Related]
13. Inflammatory breast carcinoma: an immunohistochemical study using monoclonal anti-pHER-2/neu, pS2, cathepsin, ER and PR. Charpin C; Bonnier P; Khouzami A; Vacheret H; Andrac L; Lavaut MN; Allasia C; Piana L Anticancer Res; 1992; 12(3):591-7. PubMed ID: 1352440 [TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical detection of sex steroid receptors in breast cancer using routine paraffin sections: comparison with frozen sections and enzyme immunoassay. Elias JM; Margiotta M; Sexton TR; Heimann A J Cell Biochem Suppl; 1994; 19():126-33. PubMed ID: 7823584 [TBL] [Abstract][Full Text] [Related]
15. pS2 protein status fails to be an independent prognostic factor in an average breast cancer population. Speiser P; Stolzlechner J; Haider K; Heinzl H; Jakesz R; Pecherstorfer M; Rosen H; Sevelda P; Zeilliger R Anticancer Res; 1994; 14(5B):2125-30. PubMed ID: 7840511 [TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical determination of pS2 in invasive breast carcinomas: a study on 942 cases. Soubeyran I; Wafflart J; Bonichon F; de Mascarel I; Trojani M; Durand M; Avril A; Coindre JM Breast Cancer Res Treat; 1995 May; 34(2):119-28. PubMed ID: 7647329 [TBL] [Abstract][Full Text] [Related]
17. Clinicopathological study of the expression of hsp27, pS2, cathepsin D and metallothionein in primary invasive breast cancer. Ioachim E; Tsanou E; Briasoulis E; Batsis Ch; Karavasilis V; Charchanti A; Pavlidis N; Agnantis NJ Breast; 2003 Apr; 12(2):111-9. PubMed ID: 14659340 [TBL] [Abstract][Full Text] [Related]
18. Cytosolic levels of estrogen-regulated pS2 protein in breast cancer: correlation with tumor proliferative activity. Correale M; Paradiso A; Abbate I; Mangia A; Dragone CD; Tedone T; Filotico R; Schittulli F; De Lena M Tumour Biol; 1993; 14(1):30-7. PubMed ID: 8493448 [TBL] [Abstract][Full Text] [Related]
19. pS2 (TFF1) levels in human breast cancer tumor samples: correlation with clinical and histological prognostic markers. Gillesby BE; Zacharewski TR Breast Cancer Res Treat; 1999 Aug; 56(3):253-65. PubMed ID: 10573116 [TBL] [Abstract][Full Text] [Related]
20. [Breast carcinoma: evaluation of hormone receptors and pS2, erb-B2, P-glycoprotein and Ki-67 markers]. Abadjian G; Antoun R J Med Liban; 1996; 44(1):10-5. PubMed ID: 8965315 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]